The reduction of pain by chondrocytes secreting TGF-β1 in a rat monosodium iodoacetate (MIA)-induced osteoarthritis model  by Choi, K.B. et al.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S268bunionectomy with osteotomy and ﬁxation under regional anesthesia.
Patients with a pain intensity rating of 40mm on a 100mm Visual
Analog Scale (VAS) were randomized to receive indomethacin submi-
cron particle capsules (40mg TID or BID or 20mg TID), celecoxib (400mg
loading dose; 200mg BID), or placebo. The primary endpoint was the
summed pain intensity difference measured by VAS over 48 hrs (VAS
SPID-48).
Results: Of the 462 patients enrolled, most (83.1%) were women with
a mean age of 41.2 (12.5) years. Indomethacin submicron particle
capsules 40mg TID (509.691.9), 40mg BID (328.092.9), and 20mg TID
(380.592.9) reduced pain (VAS SPID-48; P0.046 for all 3 groups)
compared with placebo (67.891.4; Figure). Although there was some
evidence of analgesia for celecoxib (279.491.9) VAS SPID-48 did not
achieve statistical signiﬁcance compared with placebo. Indomethacin
submicron particle capsules 40mg TID (30.7; P¼0.013) and 40mg BID
(29.8; P¼0.014) achieved better pain control over 4 hrs after study entry
(VAS SPID-4) compared to placebo (8.9). Similarly, indomethacin
submicron particle capsules 40mg TID (2.5; P¼0.003) and 40mg BID
(2.1; P¼0.022) provided greater total pain relief over 4 hrs after study
entry (TOTPAR-4) compared with placebo (1.2). Some evidence of pain
control was observed as early as 30 min (VAS SPID) in the indomethacin
submicron particle capsules 40mg TID (2.9) and 40mg BID (2.6) groups
compared with placebo (0.2). AEs were generally similar across treat-
ment groups and included nausea, localized post-procedural edema,
dizziness, and headache.
ĂConclusions: In this study, investigational lower-dose, indomethacin
submicron particle capsules provided effective pain control compared
with placebo in a post-surgical model of moderate to severe acute pain.
Indomethacin submicron particle capsules are a potentially promising
option for patients with acute pain.
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ACUTE AND SHORT-TERM EFFECTS OF INTRA-ARTICULAR KNEE PAIN
RELIEF ON PAIN SENSITIZATION IN KNEE OA: A COHORT STUDY
T. Joergensen y, T. Graven-Nielsen z, S. Rosager y, L. Klokker y,
K. Ellegaard y, B. Danneskiold-Samsoee y, H. Bliddal y, M.
Henriksen y. y The Parker Inst., Dept. of Rheumatology, Copenhagen Univ.Table 1
Test day Day -8 Day 0
Test 1 Test 2
Mean SE Mean
Current knee pain, cm (0-10) 3.0 0.3 2.8
Hand-held algometer, kPa
Corpus Hoffa medial 558.1 23.8 582.1
Corpus Hoffa lateral 611.2 25.3 656.5
Lateral joint line 490.6 17.3 524.6
Quadriceps tendon, lateral 507.6 23.5 527.9
Quadriceps tendon, median 580.2 22.9 597.1
Quadriceps tendon, medial 490.4 21.3 538.3
Medial joint line 506.1 23.3 513.5
Centre of patella 629.0 23.7 669.5
Extensor carpi radialis (control point) 412.0 16.1 430.5Hosp., Frederiksberg, Denmark; zCtr. for Sensory-Motor Interaction,
Dept. of Hlth.Sci. and Technology, Faculty of Med., Aalborg Univ.,
Aalborg, Denmark
Purpose: Pain is the cardinal symptom of knee osteoarthritis (OA).
Recently hyperalgesia and widespread pain was shown in knee OA
patients, as both the knee and surrounding sites were hypersensitive
to pressure pain testing compared with controls. Hyperalgesia and
spontaneous pain in knee OA is most likely related to increased
sensitivity of nociceptors located in deep tissue (peripheral sensitisa-
tion) and/or by increased responses in dorsal horn or supraspinal
neurons (central sensitisation). However, the effects of pain relief on
pain sensitivity in knee OA are unknown. The purpose of this study
was to assess the effects of intra-articular pain relief and anti-
inﬂammation on pain sensitivity in the knee and surrounding tissues
in knee OA patients.
Methods: Twenty-ﬁve consecutive knee OA patients with symptomatic
knee OA according to the ACR criteria were included in this observa-
tional study, with tests of pressure pain thresholds (PPT) before and
after treatment of the knee with intra-articular injection of 40 ml
glucocorticoid (depomedrol 40 mg/ml) and 10 ml lidocaine (10%). The
patients rated their current pain continuously on a visual analogue scale
(VAS), with 0 indicating “no pain” and 10 deﬁned “maximum pain”.
Hand-held, computer-controlled and cuff pressure algometers were
used to assess PPT in the peripatellar region, on vastus lateralis, on
tibialis anterior and the extensor carpi radialis longus muscles (control
site). The PPTs were assessed on day -8 and day 0 before, immediately
after the injection (day 0) and two weeks after the injection (day 14).
Results: The current knee painwas signiﬁcantly lower (see table 1) after
treatment, indicating clinical efﬁcacy of the injection. We found
reduced pain sensitivity (higher PPT levels) following intra-articular
lidocaine (see table 1 and 2 at day 0 - post lidocaine) in both the knee
and in the surrounding muscles, whereas the control assessment site
was not affected by either treatments. There was a trend towards even
greater reduction in pain sensitivity at day 14 after the intra-articular
treatment (see table 1 and 2 at day 14 follow-up) in both the knee and in
the surrounding muscles.
Conclusions: This study shows that intra-articular knee pain relief
leads to reduced pain sensitivity in the knee and surrounding muscles
as well. This effect may be more pronounced after a combination of
anaesthetic action and reduction of inﬂammation. Deeper under-
standing of the underlying mechanisms may inﬂuence the choice of
treatment in the future to avoid or prevent hypersensitivity in knee OA
patients.
Acknowledgments: This study was supported by grants from The Oak
Foundation, Center for Sensory-Motor Interaction (SMI) at Aalborg
University and The Danish Agency for Science Technology and Inno-
vation (FI).
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THE REDUCTION OF PAIN BY CHONDROCYTES SECRETING TGF-b1 IN
A RAT MONOSODIUM IODOACETATE (MIA)-INDUCED
OSTEOARTHRITIS MODEL
K.B. Choi, Sr., Hyeon Youl Lee, Dae-Wook Kim, Sujeong Kim. Kolon Life
Sci., Seoul, Republic of KoreaDay 14 P for trend
Post lidocaine Follow-up(post
steroid)
SE Mean SE Mean SE
0.3 1.8 0.3 1.3 0.3 0.0001
23.8 659.6 23.8 689.3 24.2 0.0001
25.3 689.8 25.3 722.9 25.8 0.0057
17.3 601.3 17.3 573.8 17.6 <.0001
23.6 636.8 23.6 560.9 23.9 <.0001
22.9 675.3 22.9 672.8 23.4 0.0011
21.3 625.3 21.3 582.9 21.8 <.0001
23.3 596.5 23.3 568.3 23.6 0.0006
23.7 707.3 23.7 702.3 24.1 0.0341
16.1 452.5 16.1 428.7 16.5 0.3013
Table 2
Test day Day -8 Day 0 Day 14 P for trend
Test 1 Test 2 Post lidocaine Follow-up(post
steroid)
Mean SE Mean SE Mean SE Mean SE
Computer-controlled algometer, kg
Corpus Hoffa 2.4 0.1 2.4 0.1 2.8 0.1 3.2 0.1 <.0001
Vastus lateralis 2.4 0.1 2.5 0.1 2.9 0.1 3.0 0.1 <.0001
Tibialis anterior 2.8 0.1 2.6 0.1 2.8 0.1 3.1 0.1 0.0006
Cuff algometer, kPa
Lower leg 15.6 0.4 15.4 0.4 16.0 0.4 15.9 0.4 0.0214
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S269Purpose: TissueGene-C (TG-C) is a mixture of normal human chon-
drocytes (hChonJ) and genetically modiﬁed chondrocytes to express
TGF-b1 (hChonJb#7), and currently undergoing phase 2 clinical trials
for osteoarthritis. Phase 2a clinical trials have shown that TG-C treat-
ment signiﬁcantly reduced pain when administered to the osteoar-
thritic patients. In this study, we investigated the effect on pain
reduction by the chondrocytes expressing TGF-b (hChonJb#7) which is
a component of TG-C.
Methods: Monosodium iodoacetate (MIA)-induced osteoarthritis rat
model was used in the study. Three milligram of MIA was intra-
articularly injected into the left knee of SD rat (280-300g) to induce
degradation of cartilage (Ponomis et al, Pain; 2005: 339). The rats
showing pain-related behaviors measured by von Frey ﬁlament test
were selected for the evaluation of hChonJb#7. At two weeks post MIA
administration, various doses of hChonJb#7were injected into the same
knee. The effect on the mechanical allodynia by hChonJb#7 treatment
was evaluated by von Frey ﬁlament test. After completing the ﬁlament
tests, the knees were harvested for the histological analysis in the
cartilage.
Results: The improvement of pain related behavior was dose-depen-
dently observed earliest from 1 week post hChonJb#7 injections. The
minimum effective dose was 3 x 10^4 cells of hChonJb#7. The effect was
maintained upto 4 week post hChonJb#7 injections. The histological
analysis showed that the integrity of cartilage was severely affected by
MIA treatment but hChonJb#7 treatment protected the cartilage from
MIA-induced damage when compared with the untreated group.
Conclusions: The current study indicated that the chondrocytes
expressing TGF-b (hChonJb#7) reduced pain in a rat model whichmight
explain pain reduction in osteoarthritis patients demonstrated during
the clinical trials.
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A SELECTIVE CCR2 ANTAGONIST SHOWED MONOCYTES MIGRATION-
INDEPENDENT ANALGESIA IN RAT MODELS OF INFLAMMATORY
PAIN
L. Corradini y, S. Hobbie z, S. Frattini x, B. Stierstorfer z,
H. Doods y. yBoehringer-Ingelheim Pharma GmbH & Co. KG, Dept. CNS
Diseases Res., Biberach an der Riss, Germany; zBoehringer-Ingelheim
Pharma GmbH & Co. KG, Biberach an der Riss, Germany; xBoehringer-
Ingelheim Pharma GmbH & Co. KG, Milan, Italy
Purpose: The aim of this study is to demonstrate whether the Che-
mokine C-C motif (CCR2) receptor is involved in inﬂammatory pain and
which mechanisms could describe its physiological contribution in pain
pathways.
Methods: Compound A was tested for in vitro properties in native cells
(rat whole blood assay) and recombinant cells lines (CHO cells
expressing rat CCR2). Binding assay was performed in rat CCR2 receptor
membrane (RMB) while functional assays were rat whole blood
monocytes shape change and calcium mobilization assay in CHO cell
line. Selectivity over CCR5 was investigated by binding assay on CHO
cells expressing rat CCR5.
To assess the in vivo proﬁle of compound A, adult (200-275 g) male
Wistar-Han (Charles River, Germany) rats undergone intraplantar
injection of complete Freund's adjuvant (CFA, 25ug/ul by Sigma Aldrich)
or intraarticular injection with 1 mg of monosodium iodoacetate (MIA,
50 ul by Sigma Aldrich) for induction of paw inﬂammatory pain or
osteoarthritis (OA), respectively.
Analgesic properties of compound A were assessed by using paw
pressure test (Randall Selitto test, UgoBasile, Italy) at 24 hrs post CFA
injection and by Incapacitance tester (manufactured by Boehringer-Ingelheim) the weight bearing (WB) deﬁcit was assessed at 3 days post
MIA injection. In addition anti-edema properties were investigated in
the CFA model measuring changes in the paw volume as assessed by
pletysmography (UgoBasile, Italy).
Tissues were collected from injured paws or joints, for further histo-
logical examination. All experimental procedures were approved by the
ethics committee and the Regierungspräsidium Tübingen (VVH
06-007).
Results: In rat compound A is a selective CCR2 antagonist with Ki in rat
RMB of 3.6 nM, with no binding properties to the closest homologous
CCR5 (Ki¼2920 nM). In addition, it reversed monocytes shape changes
(IC50 4.3 nM) and inhibited Calcium mobilization in CHO cells
(IC50¼1.4 nM) proving to be a full antagonist devoid of any agonistic
activity.
In the CFA model, Compound A showed a dose dependent anti-hyper-
algesic effect after acute treatment. The highest dose of 10 mg/kg, orally
(PO) achieved full effect comparable to celecoxib (30 mg/kg, PO) while
the minimal effective dose was measured at 1 mg/kg, PO. Moreover,
unlike celecoxib repeated doses of compound A did not prevent edema
formation in the CFA model.
In the MIA model compound A, like celecoxib, showed no effect in the
WB deﬁcit when dosed acutely, however it signiﬁcantly reversed pain-
like behaviour when given by subchronic treatment. Furthermore
histological ﬁndings revealed that compound A has no effect in
reducing monocytes migration in the CFA paw or MIA joint.
Conclusions: Overall our data support a CCR2 antagonist to have the
potential to provide analgesia in nociceptive pain condition. In addition
preclinical data suggest that analgesic properties of CCR2 antagonists in
pain inﬂammatory models can not be attributed to blockage of mono-
cytes migration.
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MEASUREMENT OF PAIN IN AN ACUTE MURINE ARTHRITIS PAIN
MODEL USING A DYNAMIC WEIGHT BEARING DEVICE AND EVOKED
PAIN RESPONSES: EFFECT OF INTRA-ARTICULAR CAPSAICIN
PRETREATMENT
H.E. Krug y,z, C. Dorman z, S. Funkenbusch z, S. Frizelle z,
M. Mahowald y,z. yUniv. of Minnesota, Minneapolis, MN, USA;
zMinneapolis VA Hlth.Care System, Minneapolis, MN, USA
Purpose:Murine models are important to study arthritis pain and new
analgesics, but the measurement of pain in mice is challenging. The
DynamicWeight Bearing (DWB) device measures individual limb forces
and time spent bearing weight on each limb during spontaneous
activity. Evoked pain behaviors in mice are sensitive to change due to
arthritis pain and analgesia. We hypothesized that mice with acute
arthritis would have measurable changes in DWB due to joint pain that
would correlate with evoked pain behaviors and that this could be
prevented by pre-treating with intra-articular (IA) capsaicin. We
measured DWB and Evoked Pain Scores (EPS) in acute arthritis to
determine if DWB correlates with EPS and whether it is a reliable
measure of spontaneous pain behavior in animals with arthritis. To test
the reliability of DWB in differentiating arthritic from nonarthritic
animals, some mice were pretreated with capsaicin to prevent devel-
opment of arthritis. We also measured substance P in the dorsal root
ganglia of animals with andwithout arthritis and withmorphine (MOR)
and capsaicin (CAP) treatment.
Methods: C57Bl6 mice were used for all experiments. Acute inﬂam-
matory arthritis was produced by IA injection of 10ml 2.5% carrageenan
into the left knee 2-4 hours prior to pain behavior testing. Analgesic
controls were injected with 2.5% carrageenan diluted in MOR solution
